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Introduction: No study has examined structural brain changes spe-
cifically associated with chemotherapy in a lung cancer population. 
The aim of this cross-sectional study was to assess differences in 
brain structure between small-cell lung cancer patients (C+) follow-
ing chemotherapy, non–small-cell lung cancer patients (C−) before 
chemotherapy and healthy controls (HC).
Methods: Twenty-eight small-cell lung cancer patients underwent a 
neuropsychological assessment and a structural magnetic resonance 
imaging, including T1-weighted and diffusion tensor imaging to 
examine gray matter density and white matter (WM) integrity, respec-
tively, 1 month following completion of platinum-based chemother-
apy. This group was compared with 20 age and education-matched 
non–small-cell lung cancer patients before receiving chemotherapy 
and 20 HC.
Results: Both C+ and C− groups exhibited cognitive impairment com-
pared with the HC group. The C+ group performed significantly worse 
than HC in verbal fluency and visuospatial subtests; C− performed 
significantly worse than both C+ and HC in verbal memory. Voxel-
based morphometry analysis revealed lower gray matter density in the 
insula and parahippocampal gyrus bilaterally, and left anterior cingu-
late cortex in C+ compared with HC. Diffusion tensor imaging indices 
showed focal decreased WM integrity in left cingulum and bilateral 
inferior longitudinal fasciculus in the C+ group and more widespread 
decreased integrity in the C− group compared with the HC group.
Conclusion: This study demonstrates that lung cancer patients 
exhibit cognitive impairment before and after chemotherapy. Before 
the treatment, C− showed verbal memory deficits as well as a wide-
spread WM damage. Following treatment, the C+ group performed 
exhibited lower visuospatial and verbal fluency abilities, together 
with structural gray matter and WM differences in bilateral regions 
integrating the paralimbic system.
Key Words: Lung cancer, Chemotherapy, Cognitive impairment, 
Neuroimaging, Diffusion tensor imaging, Voxel-based morphometry.
(J Thorac Oncol. 2015;10: 38–45)
Chemotherapy-induced cognitive impairment or “chemo-brain” is a well-recognized clinical syndrome, consist-
ing of subtle to moderate cognitive changes across various 
domains.1 Although acute cognitive changes during chemo-
therapy are common,2 long-term cognitive changes post-
treatment may persist in only a subgroup (17–34%) of cancer 
survivors.3 In recent years, several studies using neuroimaging 
(magnetic resonance imaging[MRI]) techniques have reported 
structural brain changes associated with chemotherapy.4 These 
changes consist of an early, diffuse gray matter (GM) decrease 
and white matter (WM) degeneration5–9 with some studies find-
ing persistent structural alterations at longer intervals.5,6,10–13 
Additionally, a widespread decrease in WM volume has been 
described in cancer patients before chemotherapy.14 This WM 
decrease is supported by several neuropsychological stud-
ies describing a lower cognitive performance in a subset of 
patients before adjuvant treatment,15,16 suggesting that cancer 
itself might have a negative effect on cognitive processing.
To date, the majority of investigations on treatment- and 
cancer-related cognitive changes have focused on breast can-
cer patients. Cognitive effects in non–small-cell (NSCLC) and 
small-cell (SCLC) lung cancers, specifically, have not been 
extensively studied, potentially because of the fact that lung 
cancer is associated with shorter survival, has confounding 
co-morbidities and, for SCLC, additional treatments such as 
prophylactic cranial irradiation (PCI) are needed. Thus, the 
study of the near- or long-term effects of chemotherapy on 
cognition in this population remains challenging and under-
represented in the literature.
The handful of studies that have focused on lung cancer 
patients found cognitive deficits early following chemotherapy 
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treatment, with special emphasis on executive function, ver-
bal fluency, and verbal memory.17–20 Early prospective stud-
ies examining neuropsychological performance in NSCLC 
patients found a marked cognitive decline 1 month post-
chemotherapy with relative improvement at 7 months follow-
up.20–22 Other studies, focusing on SCLC patients, found that 
nearly 60 to 90% of the patients were cognitively impaired 1 
to 5 months after the end of chemotherapy.17–19,23,24
While the results of these studies are suggestive, little 
is known about the underlying structural or functional brain 
alterations following lung cancer chemotherapy treatment. We 
compared SCLC patients 1 month following chemotherapy 
(C+) with NSCLC patients before chemotherapy (C−) and 
healthy control (HC) groups in gray matter density (GMD) 
and WM integrity using structural MRI together with neuro-
psychological assessment.
Patients and Methods
Patients
The patients were prospectively recruited from 
December 2010 to March 2013 from the Lung Cancer Unit 
of the ICO Duran i Reynals-Hospital Universitari de Bellvitge 
(n = 40) and from the Radiation Oncology Department of the 
ICO Badalona-Hospital Germans Trias i Pujol (n = 8). Patients 
were eligible if they had a histologically proven diagnosis of 
either NSCLC or SCLC, were between the ages of 40 and 70 
years, had no severe concomitant systemic illness or psychi-
atric disorder with a negative impact on cognitive function, or 
had any contraindication to undergo MRI. The patients were 
excluded if they had an evidence of brain metastases on MRI. 
This cross-sectional analysis represents a part of an ongo-
ing longitudinal study specifically designed to examine the 
effects of prophylactic cranial irradiation (PCI) on cognition 
in SCLC patients. SCLC patients (C+, n = 28) who were eli-
gible to receive PCI and were anti-HU negative were enrolled 
1 month following completion of chemotherapy and before 
PCI. However, to delineate the effects specific to chemother-
apy over time, the SCLC group was contrasted with a NSCLC 
group, since SCLC patients receive PCI, thus confounding 
potential effects of PCI with chemotherapy. NSCLC group 
underwent the same platinum-based chemotherapy and did not 
receive PCI, facilitating the study of the long-term effects of 
chemotherapy in the longitudinal study. NSCLC patients (C−, 
n = 20) who were eligible to receive platinum-based chemo-
therapy were enrolled in the study before the initiation of che-
motherapy. NSCLC was selected as the cancer control group 
because of its higher incidence, especially in comparison with 
SCLC. The recruitment of lung cancer patients before the ini-
tiation of treatment just after cancer diagnosis is very chal-
lenging. Patients are overwhelmed with several diagnostic 
tests and therefore less predisposed to collaborate in a trial. 
Thus, recruitment of the NSCLC group before chemotherapy 
facilitated the achievement of our designated sample size. Age 
and education-matched HC (n = 20) who met the same inclu-
sion (except for cancer diagnosis) and exclusion criteria were 
recruited through community advertisements. Vascular risk 
factors were collected and classified in low-risk (if the patient 
had none or one risk factor) and high-risk (if the patient had 
two or more risk factors) groups.19 The study protocol was 
approved by the local Ethical Commission and informed con-
sent was obtained from all participants. All statistical analysis 
was conducted in SPSS 18.0 (SPSS, Chicago, IL). One-way 
analysis of variance and Chi-square tests were used to test the 
group differences with a critical p-threshold of 0.05.
neuropsychological assessment
The patients were evaluated using the Mattis Dementia 
Rating Scale-2; selected subtests of the Spanish version 
of the Wechsler Adult Intelligence Scale-III (Vocabulary; 
Information; Similarities; Digit Span; Letter Number 
Sequencing; Block Design; Matrix Reasoning; Picture 
Completion); Rey Auditory Verbal Learning test; Wechsler 
Memory Scale–III Logical Memory I-II; Rey-Osterreith 
Complex Figure Test Copy, Immediate or First and Delayed; 
Spanish version of the Boston naming test; Verbal Fluency 
test (phonemic and semantic); Trail Making Test (A-B); and 
Beck Depression Inventory (BDI). Intelligence quotient was 
estimated using Vocabulary performance. Raw cognitive test 
scores were compared with the validated Spanish norma-
tive values, corrected for age and education, and converted 
into z-scores. Cognitive impairment was defined as a Mattis 
Dementia Rating Scale-2 raw score less than 123,25 one test 
greater than or equal to 2 or two tests greater than or equal to 
1.5 SDs below the sample mean.26
structural neuroimaging
MRI scan acquisition
The participants were imaged on a 3-Tesla MRI 
(Siemens Magnetom Trio Tim SyngoB17; Siemens AG, 
Munich, Germany) with a 32-channel phased-array head coil. 
High-resolution structural images were obtained using magne-
tization-prepared, rapid-acquired gradient echo sequence (240 
slices sagittal, TR (repetition = 2300 ms, TE = 2.98 ms, 1-mm 
isotropic voxels) and a whole-brain diffusion MRI sequence 
using diffusion tensor spin echo planar imaging was acquired 
(voxel size of 2.5 × 2.5 × 2.5 mm, matrix of 96 × 96, 55 slices 
with 2.5 mm-thick and no gap, TE = 98 ms, TR = 9600 ms, EPI 
factor = 96, field of view = 240 mm, bandwidth = 1022 Hz, 
echo-spacing = 1.08 ms, b-value = 1000 s/mm2). One single 
run of 64 diffusion-weighted directions with one nondiffu-
sion-weighted volume was acquired. Finally, a fluid attenu-
ated inversion recovery sequence was acquired (64 slices 
with 2.0 mm-thick, TE = 145 ms, TR = 9000 ms, voxel size 
1.0 × 0.9 × 2.0 mm).
t1 image processing and analysis
Morphometric analysis was carried out using voxel-based 
morphometry27 and processed using MATLAB version 7.8.0 
(The MathWorks Inc., Natick, MA) and Statistical Parametric 
Mapping software (SPM8; The Welcome Department of 
Imaging Neuroscience, London). T1 images were segmented,28 
the resulting Gray Matter (GM) tissue probability maps normal-
ized into Montreal Neurological Institute (MNI) space using 
diffeomorphic anatomical registration through exponentiated 
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lie algebra (DARTEL)29,30 and smoothed using an isotropic 
spatial smoothing kernel (8 mm).
The individual smoothed GM density (GMD) images 
were entered into a second-level analysis using a one-way 
ANOVA model with the between subject variable of Group 
(HC; C−; C+). Four independent two-sample t tests were then 
conducted: C+ and C− versus HC, C+ versus HC, C− versus 
HC, C+ versus C−. For all the contrasts, a p lesser than or equal 
to 0.05 family-wise-error corrected at the cluster level was used, 
with an auxiliary p less than 0.001 uncorrected at the voxel level.
Diffusion-weighted imaging processing and analysis
Diffusion data processing was started by correcting 
for eddy current distortions and head motion using FMRIB’s 
Diffusion Toolbox (FDT)(FSL 5.0.1, www.fmrib.ox.ac.
uk/fsl/).31 The gradient matrix was then rotated32 and brain 
extraction was performed using the brain extraction tool.33 
The analysis continued with the reconstruction of the diffu-
sion tensors using the linear least-squares algorithm included 
in the Diffusion Toolkit 0.6.2.2 (Ruopeng Wang, Van Wedeen, 
trackvis.org/dtk, Martinos Center for Biomedical Imaging, 
Massachusetts General Hospital). Finally, fractional anisot-
ropy (FA), radial diffusivity (RD), and axial diffusivity (AD) 
maps for each subject were calculated using the eigenvalues 
(ʎ1, ʎ2, and ʎ3) extracted from the diffusion tensors.
FA, AD (ʎ1), and RD (ʎ2 + ʎ3/2) maps were regis-
tered to the MNI Functional Magnetic Resonance Imaging 
of the Brain or FMRIB's high-resolution average of 58 well-
aligned good quality FA images (FMRIB58_FA) template 
using FMRIB's nonlinear image registration tool (FNIRT).34,35 
The resulting FA, RD, and AD maps were fed into a second-
level SPM8 analysis using a one-way ANOVA model with 
the between subject variable of Group (HC; C−; C+). Four 
independent two-sample t tests were then conducted: C+ and 
C− versus HC, C+ versus HC, C− versus HC, C+ versus C−. 
For all the contrasts, a p less than or equal to 0.05 uncorrected 
threshold at the cluster level was used, with an auxiliary p less 
than 0.001 uncorrected threshold at the voxel level.
ResULts
Patient Characteristics
The study initially recruited 42 SCLC patients, 27 
NSCLC patients, and 20 HC subjects. Fourteen SCLC patients 
were excluded (six had asymptomatic brain metastases in the 
baseline MRI; four did not tolerate the MRI procedure; three 
were excluded because of technical issues with the MRI; and 
one presented severe undiagnosed dementia). Seven NSCLC 
patients were excluded (five did not tolerate the MRI proce-
dure; one did not complete all the examinations; and another 
patient was excluded because of technical issues with the 
MRI). The final groups consisted of 28 patients in the C+ 
group, 20 in the C− group, and 20 subjects in the HC group.
Characteristics of the entire cohort are described in 
Table 1. There were no significant differences between the 
groups in age, gender, education, or grouped vascular risk 
factors. When analyzed independently, smoking history 
showed a significant difference between lung cancer patients 
and HC (Fisher exact test, p < 0.0001), with no differences 
between both the cancer groups (C+ and C−, Fisher exact test, 
p > 0.34). Diabetes mellitus type II (DMII) showed a signifi-
cantly higher incidence in lung cancer patients (χ2(2) = 6.86, 
p < 0.03) but did not differ between the lung cancer groups (C+ 
and C−, χ2 (1) = 3.02, p > 0.08). Disease and treatment-related 
characteristics of C+ and C− group are described in Table 2.
neuropsychological assessment
The neuropsychological assessment revealed that lung 
cancer patients performed significantly worse than the healthy 
controls in several subtests. Both the cancer groups exhibited 
a higher rate of cognitive impairment (39% of C+ and 30% of 
C−) compared with the healthy controls (5%) (χ2 (2) = 7.23, p 
< 0.027). However, there were no differences between the lung 
cancer groups (χ2 (1) = 0.44, p > 0.5). See Supplementary 
Table S1 (Supplemental Digital Content, http://links.lww.
com/JTO/A702) and Figure 1.
structural neuroimaging
Voxel-based morphometry
The analysis revealed differences in GMD between the 
groups, mainly in paralimbic regions (Fig. 2). Further pair-
wise t test analyses showed significant decrease in GMD for 
lung cancer patients (C+; C−) compared with the HC group in 
several brain regions including left insula, bilateral parahippo-
campal gyrus (PHG) and left anterior cingulate cortex (ACC). 
No regions exhibited less GMD in the HC group compared 
with either cancer group.
In the direct contrast between C+ and HC (Fig. 2), a sig-
nificant decrease in GMD was exhibited in the right insula, 
bilateral PHG, and left ACC. No regions exhibited less GMD in 
taBLe 1.  Baseline Demographics and Vascular Risk Factors 
of the Entire Cohort
C+ (n = 28) C− (n = 20) HC (n = 20) p
Age (years)a 59.29 ± 5.58 60.30 ± 6.37 62.3 ± 8.08 0.30
Genderb
  Male 22 (79) 18 (90) 18 (90) 0.42
  Female 6 (21) 2 (10) 2 (10)
Education (years)c 7.50 (0.17) 8.50 (0.16) 8 (6.19) 0.66
Estimated verbal IQa 10.96 (3.35) 10.90 (3.13) 12.20 (3.17) 0.20
Smokingb 28 (100) 19 (95) 11 (55) 0.0001
Alcoholb 4 (29) 8 (20) 10 (50) 0.11
HTb 10 (36) 10 (50) 7 (35) 0.53
DM type IIb 6 (21) 9 (45) 2 (10) 0.03d
Dyslipidemiab 9 (32) 11 (55) 11 (55) 0.18
Vascular risk factorsb
  Low-risk (0 or 1) 13 (46) 4 (20) 8 (40) 0.16
  High-risk (≥2) 15 (54) 16 (80) 12 (60)
aMean ± SD.
bn (%).
cMedian (range).
dDM type II was not significant between C+ and C– (p ˃ 0.08).
C+, chemotherapy-treated small-cell lung cancer group; C−, nonchemotherapy 
treated non–small-cell lung cancer group; HC, healthy control group; IQ, intelligence 
quotient; HT, hypertension; DM, diabetes mellitus.
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the HC group compared with the C+ group. No significant dif-
ferences were observed between the C+ and the C− groups or 
between the C− and the HC group. See Supplementary Table S2 
(Supplemental Digital Content, http://links.lww.com/JTO/A702).
Diffusion tensor imaging-voxel based analysis
Between-group analysis found fractional anisotropy (FA) 
differences in the left cingulum and left inferior longitudinal 
fasciculus (ILF), right superior longitudinal fasciculus (SLF) 
and left superior corona radiata (SCR), and axial diffusivity 
(AD) differences especially focused in left cingulum. No sig-
nificant differences were exhibited in RD between groups. FA 
is a highly sensitive but nonspecific biomarker of neuropathol-
ogy and microstructural architecture,36 and AD represents the 
main diffusion direction aligned to the WM tracts and has been 
associated with several neuropathological changes especially 
related to axonal damage. Specifically, the increase of AD has 
been related to inflammatory processes and axonal atrophy.37
In the following pairwise t test analyses (C+ and C− ver-
sus HC, C+ versus HC, C− versus HC, C+ versus C−), lung 
cancer patients (C+ and C−) versus HC, C+ versus HC, and C− 
versus HC comparisons revealed significant differences. Lung 
cancer patients exhibited less WM integrity (lower FA and 
higher AD values) compared with HC in left ILF. Voxel-based 
t test analysis comparing C+ versus HC found significantly 
higher AD in left cingulum compared with HC. Additionally, 
the C− group exhibited lower WM integrity (lower FA and 
higher AD) in widespread regions, involving left cingulum 
and SCR, and right SLF. The comparison between C+ and C− 
found no significant differences. In brief, the DTI results were 
broadly concordant between the comparisons, even though 
the C− group pattern of effects was more extensive than that 
for the C+ group. See Supplementary Table S3 (Supplemental 
Digital Content, http://links.lww.com/JTO/A702).
disCUssion
This is the first study to document neuropsychologi-
cal and structural neuroimaging changes in a cohort of 
taBLe 2.  Disease and Treatment-Related Characteristics of 
the Patients
C+ (n = 28) C– (n = 20) p
KPSa 80 (70–100) 90 (70–100) 0.08
Histologyb
  SCLC 28 (100)
  NSCLC
   Adenocarcinoma 11 (55)
   Squamous-cell carcinoma 8 (40)
   Nonclassified 1 (5)
Tumor stageb
  Limited disease 22 (79)
  Extensive disease 6 (21)
  IIB 2 (10)
  IIIA 11 (55)
  IIIB 7(35)
Chemo typeb
  CDDP-based 21 (75)
  CBDCA-based 7 (25)
Number of chemo cyclesa 4 (3–6)
Thoracic radiationb 25 (89)
amedian (range).
b n (%).
C+, chemotherapy-treated small-cell lung cancer group; C−, nonchemotherapy treated 
non–small-cell lung cancer group; KPS, Karnosfky performance scale; SCLC, small-cell 
lung cancer; NSCLC, non–small-cell lung cancer; CDDP, cisplatin; CBDCA, carboplatin.
FiGURe 1.  Neuropsychological results. 
Significant differences between the groups 
on neuropsychological testing. ROCF, Rey-
Osterrieth complex figure.
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small-cell lung cancer patients (SCLC, C+) treated with 
platinum-based chemotherapy. Our results revealed that 
patients in the C+ group exhibited cognitive impairment 
shortly after chemotherapy treatment, with special empha-
sis in visuospatial abilities and verbal fluency together with 
lower GMD in bilateral paralimbic regions and lower WM 
integrity in overlapping WM tracts. Additionally, before 
treatment, the C− group exhibited cognitive deficits in 
verbal working memory together with widespread WM 
decreases. These neuropsychological and structural imag-
ing findings suggest that both cancer and cancer treatment 
may be associated with the development of central nervous 
system toxicity.
One-third of the patients in both lung cancer groups met 
the criteria for cognitive impairment; however, the neuropsy-
chological profile was quite different. Following treatment, the 
C+ group performed worse than the HC group in visuospatial 
measures and verbal phonemic fluency. These cognitive defi-
cits are similar to those previously described in breast cancer 
patients following chemotherapy.1 The NSCLC (C−) group 
performed worse than HC and C+ in long-term working ver-
bal memory. Significantly, these cognitive deficits, especially 
FiGURe 2.  Group differences for regional gray matter density (GMD) between groups. Group effect: The analysis revealed 
significant effects for group (C+, C−, HC [healthy controls]) in regional GMD in insula and parahippocampal gyrus (PHG) bilat-
erally and left anterior cingulate cortex (ACC). The results are displayed on an F-map and superimposed on an a-priori created 
T1 structural magnetic resonance imaging (MRI) template in standard stereotactic space. C+ and C− decreases compared with 
HC: The pairwise t test comparison between the cancer groups (C+ and C−) and HC group showed significant decreases in 
GMD of both the cancer groups in similar regions: left insula, bilateral PHG, and left ACC. The results are displayed on a  
T-map and superimposed on an a-priori created T1 structural MRI template in standard stereotactic space. C+ decreases 
compared with HC: The pairwise t test comparison between C+ and HC groups showed significant decreases of GMD in 
similar regions: right insula, bilateral PHG, and left ACC. The results are displayed on a T-map and superimposed on an a-priori 
created T1 structural MRI template in standard stereotactic space. L, left; R, right, PHG, parahippocampal gyrus; ACC, anterior 
cingulate cortex.
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in verbal working memory, have been described in cancer 
patients before the initiation of therapy.15,16 Although cogni-
tive changes associated with either cancer or cancer treatment 
have been extensively recognized, the pathogenesis of these 
neurocognitive changes remains unclear. In this setting, sev-
eral hypotheses have been proposed including the biology of 
cancer as well as common risk factors for the development of 
both cancer and mild cognitive changes in normal aging.3
Regarding our neuroimaging results, the C+ group pre-
sented a regional decrease in GMD in bilateral insula, bilat-
eral PHG and left ACC 1 month following chemotherapy. The 
insula and PHG are paralimbic regions that play an important 
role in linking cognition and emotion as well as in extended 
episodic memory function.38 The cingulate cortex is usually 
considered part of the limbic cortex which lies immediately 
above the corpus callosum. The ACC is widely connected 
with diverse parts of the brain and is essential in problem 
solving, error recognition, and adaptive response to changing 
conditions.39 These structural differences found in SCLC con-
firm a subset of previous findings but also identify previously 
unreported regions that may be impacted following chemo-
therapy treatment. Structural neuroimaging findings in GM 
have been identified in medial and superior frontal gyri,5,6,13,26 
parietal,11 medial temporal,5,13 and cerebellar regions.6,11,13 
The DTI results showed an increase of AD in C+ group com-
pared with HC in bilateral anterior temporal regions of the 
ILF and bilateral anterior cingulum. The ILF is an associ-
ate bundle connecting anterior-inferior temporal regions to 
parieto-occipital areas connecting visual areas to the amyg-
dala and hippocampus.40 The cingulum is a medial associa-
tive bundle projecting from the cingulate gyrus around the 
corpus callosum to the entorhinal cortex that forms the WM 
core of the cingulate gyrus to the PHG and anterior temporal 
regions. Regarding the WM findings, our results are consis-
tent with those described in the literature with the exception 
that our WM changes are less widespread and more focused 
on bilateral ILF and the cingulum.7,11 Significantly, for the 
C+ group, DTI results converge with GMD differences, and 
are concordant with observed neuropsychological deficits, 
providing strong support for acute structural and functional 
changes in bilateral paralimbic regions following chemother-
apy treatment.
Although previous research has found lower WM 
integrity following chemotherapy treatment in cancer sur-
vivors,7,8,11 WM damage specifically associated with cancer 
patients before chemotherapy is still at present less clear.8,14 
The C− group exhibited lower WM integrity in the same WM 
structures as the C+ group, with the addition of two com-
plex projection systems, the left SCR and the right SLF. The 
SCR tract contains ascending and descending fibers that 
connect the subcortical nuclei and spinal cord with the cere-
bral cortex41 and the SLF forms an anatomical connection 
between the frontal and parietal regions.42 The WM findings 
and neuropsychological deficits exhibited by the C− group 
are in line with previous findings in cancer patients before 
chemotherapy.14
FiGURe 3.  Group differences for regional 
diffusion tensor imaging (DTI) indexes (FA 
[fractional anisotropy] and AD [axial dif-
fusivity]) between groups. Statistical maps 
of decreased FA (blue color) and increased 
AD (red color) are displayed at a p-value 
of 0.01. The pairwise t test comparison 
between the lung cancer groups (C+ and 
C−) and HC group found lower white 
matter (WM) integrity in bilateral infe-
rior longitudinal fasciculus (ILF) and right 
superior longitudinal fasciculus (SLF) and 
left cingulum. The pairwise t test com-
parison between C+ and HC groups found 
lower WM integrity in bilateral ILF and left 
cingulum. The pairwise t test comparison 
between C− and HC groups found lower 
WM integrity in bilateral ILF, right SLF, 
left superior corona radiata (SCR) and left 
cingulum.
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Specific differences between our study and previous 
neuroimaging studies include demographic, clinical, dis-
ease- and treatment-related factors that might explain the dif-
ferences in the structural findings. First, patients included in 
our study were older (mean age 60 years) and less educated 
(mean education level 7 years) compared with patients in 
other studies.5,6,13,26 As a result, to control for these confound-
ing factors, an age and education-matched healthy control 
group was included. In addition, the chemotherapy regimen 
used in lung cancer patients differs from those used in breast 
cancer. Although little is known about platinum-related brain 
neurotoxicity, an association with oxidative stress and brain 
morphological and molecular changes has been described.43
Concerning vascular risk factors, only smoking and 
DMII were significantly different between the groups. As 
expected, a higher proportion of lung cancer patients had a 
smoking history and in addition, DMII was more prevalent in 
lung cancer groups. Both factors have been associated with an 
increased risk of dementia and cognitive decline.44 Given these 
vulnerabilities, lung cancer survivors may be at higher risk of 
cognitive impairment, particularly compared with breast can-
cer survivors, who are typically younger and who generally 
have less medical co morbidities. Finally, in contrast to other 
cancer types, lung cancer is commonly associated with para-
neoplastic syndromes. For this reason, only C+ patients with 
anti-HU negative antibodies were enrolled in our study.
Our study presents some limitations. The cross-sectional 
design of the study may have limited the possibility to clearly 
isolate the effect of chemotherapy from more general cancer-
related changes. Similar to our findings, previous literature 
has found cognitive, structural and functional brain alterations 
in cancer-diagnosed individuals prior to treatment.   Potential 
mechanisms include the biology of cancer, the inflammatory 
response triggering neurotoxic cytokines or common risk fac-
tors for the development of both cancer and mild cognitive 
changes,3,45 that may be associated with cognitive decline 
found in these patients. However, in addition to cognitive 
and structural changes prior to treatment, treatment with 
platinum-based chemotherapy agents may contribute to these 
cognitive changes, through DNA damage caused directly by 
the cytotoxic agents, or through increases in oxidative stress,3 
resulting in damage to both WM and GM structures together 
with a different and specific cognitive impairment profile. 
The additive effect of cancer diagnosis and treatment with 
platinum based chemotherapy agents is suggested by our find-
ings, given that the pattern of cognitive deficits and neuroana-
tomical findings were different between SCLC patients treated 
with chemotherapy versus NSCLC patients prior to treatment. 
In conclusion, our study demonstrates that NSCLC (C−) 
patients exhibit cognitive impairment at baseline, before treat-
ment, especially in verbal memory together with widespread 
WM decreases. One month following treatment, SCLC (C+) 
patients present distinct cognitive deficits especially in visuo-
spatial abilities and verbal fluency, and structural GM and 
WM differences in bilateral regions integrating the paralim-
bic system. Further prospective studies are warranted to better 
delineate the effects of cancer and cancer treatment on cogni-
tion in lung cancer population.
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